Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $85,015.60 in Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 33,080 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $2.57, for a total value of $85,015.60. Following the completion of the sale, the insider now directly owns 599,821 shares in the company, valued at $1,541,539.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, September 11th, Aladar Szalay sold 31,376 shares of Genelux stock. The stock was sold at an average price of $2.62, for a total value of $82,205.12.
• On Monday, September 9th, Aladar Szalay sold 23,383 shares of Genelux stock. The shares were sold at an average price of $2.70, for a total value of $63,134.10.
• On Tuesday, September 3rd, Aladar Szalay sold 42,818 shares of Genelux stock. The shares were sold at an average price of $2.09, for a total transaction of $89,489.62.
• On Thursday, August 29th, Aladar Szalay sold 107,045 shares of Genelux stock. The stock was sold at an average price of $1.98, for a total transaction of $211,949.10.
• On Tuesday, August 27th, Aladar Szalay sold 51,630 shares of Genelux stock. The shares were sold at an average price of $2.11, for a total transaction of $108,939.30.
• On Friday, August 23rd, Aladar Szalay sold 40,000 shares of Genelux stock. The stock was sold at an average price of $2.29, for a total value of $91,600.00.

Genelux Trading Down 8.6 %

NASDAQ GNLX opened at $2.44 on Monday. The stock’s fifty day moving average price is $2.21 and its 200-day moving average price is $3.38. The stock has a market cap of $83.82 million, a P/E ratio of -2.52 and a beta of -1.55. Genelux Co. has a 12 month low of $1.60 and a 12 month high of $30.44.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, analysts forecast that Genelux Co. will post -0.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GNLX has been the topic of several research reports. Benchmark dropped their price target on Genelux from $30.00 to $25.00 and set a “speculative buy” rating on the stock in a research report on Friday, May 31st. Roth Capital raised shares of Genelux to a “strong-buy” rating in a research report on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of Genelux in a research note on Thursday, August 15th. Finally, Roth Mkm began coverage on shares of Genelux in a research note on Tuesday, August 27th. They set a “buy” rating and a $10.00 price objective on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $22.33.

Institutional Investors Weigh In On Genelux

Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodward Diversified Capital LLC boosted its stake in Genelux by 0.3% during the 1st quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after purchasing an additional 3,687 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Genelux by 2.4% during the first quarter. Vanguard Group Inc. now owns 1,023,030 shares of the company’s stock valued at $6,578,000 after buying an additional 24,220 shares during the last quarter. Armistice Capital LLC bought a new stake in Genelux in the 2nd quarter worth about $1,755,000. Highbridge Capital Management LLC purchased a new position in Genelux in the 2nd quarter worth about $1,231,000. Finally, Affinity Asset Advisors LLC bought a new position in Genelux during the 2nd quarter valued at about $195,000. Institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.